| Identification | Back Directory | [Name]
PF-06650833 | [CAS]
1817626-54-2 | [Synonyms]
CS-2457
PF06650883
PF-06650833
PF06650833;PF 06650833
PF06650833 >=98% (HPLC)
1-(((2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide
1-[[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxo-2-pyrrolidinyl]methoxy]-7-methoxy-6-isoquinolinecarboxamide
6-Isoquinolinecarboxamide,1-(((2S,3S,4S)-3-ethyl-4-fluoro-5-oxo-2-pyrrolidinyl)methoxy)-7-methoxy- | [Molecular Formula]
C18H20FN3O4 | [MDL Number]
MFCD30343869 | [MOL File]
1817626-54-2.mol | [Molecular Weight]
361.37 |
| Chemical Properties | Back Directory | [Boiling point ]
621.0±55.0 °C(Predicted) | [density ]
1.34±0.1 g/cm3(Predicted) | [storage temp. ]
room temp | [solubility ]
DMSO : ≥ 33 mg/mL (91.32 mM) | [form ]
powder | [pka]
13.44±0.70(Predicted) | [color ]
white to beige |
| Hazard Information | Back Directory | [Biochem/physiol Actions]
PF06650833 has been studied for its use in the treatment of Waldenstrom macroglobulinemia, indicated by overproduction of IgM (immunoglobulin M)-producing lymphoplasmacytic cells. | [storage]
Store at -20°C |
|
|